Medicus Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
| 31.2* | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2* | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 97 | Medicus Pharma Ltd. Clawback Policy (incorporated by reference from Exhibit 97 to the Registrant's Annual Report on Form 10-K, filed with the SEC on March 28, 2025) |
| 101.INS* | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
- Filed herewith
- Indicates a management contract or compensatory plan.
Schedules and certain other private or confidential information (as indicated therein) have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.
† Certain private or confidential information (as indicated therein) have been redacted pursuant to Item 601(a)(6) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized, in W. Conshohocken, Pennsylvania on the 25 th day of March, 2026.
| MEDICUS PHARMA LTD. | |
|---|---|
| By: | /s/ Dr. Raza Bokhari |
| Name: | Dr. Raza Bokhari |
| Title: | Executive Chairman and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this annual report has been signed below by the following persons in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Raza Bokhari | Executive Chairman and | March 25, 2026 |
| Dr. Raza Bokhari | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| /s/ Carolyn Bonner | President and Chief Financial Officer | March 25, 2026 |
| Carolyn Bonner | (Principal Financial and | |
| Accounting Officer) | ||
| /s/ Larry Kaiser | Director | March 25, 2026 |
| Dr. Larry Kaiser | ||
| /s/ Robert J. Ciaruffoli | Director | March 25, 2026 |
| Robert J. Ciaruffoli | ||
| /s/ William L. Ashton | Director | March 25, 2026 |
| William L. Ashton | ||
| /s/ Barry Fishman | Director | March 25, 2026 |
| Barry Fishman | ||
| /s/ Sara R. May | Director | March 25, 2026 |
| Dr. Sara R. May | ||
| /s/ Cathy McMorris Rodgers | Director | March 25, 2026 |
| Hon. Cathy McMorris Rodgers | ||
| /s/ Ajay Raju | Director | March 25, 2026 |
| Ajay Raju | ||
| /s/ Patrick Mahaffy | Director | March 25, 2026 |
| Patrick Mahaffy | ||
MEDICUS PHARMA LTD.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID #274) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID #185) | F-3 |
| Consolidated Financial Statements | F-5 |
| Consolidated Balance Sheets | F-6 |
| Consolidated Statements of Operations and Comprehensive Loss | F-7 |
| Consolidated Statements of Changes in Shareholders' Equity | F-8 |
| Consolidated Statements of Cash Flows | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.